PTO- 1478 |
Approved for use through 08/31/2021. OMB 0651-0009 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |
Serial Number: 90884742 |
Filing Date: 08/16/2021 |
Input Field |
Entered |
SERIAL NUMBER | 90884742 |
---|---|
MARK INFORMATION | |
*MARK | \\TICRS\EXPORT18\IMAGEOUT 18\908\847\90884742\xml1 \ APP0002.JPG |
SPECIAL FORM | YES |
USPTO-GENERATED IMAGE | NO |
LITERAL ELEMENT | NEUROCRINE BIOSCIENCES |
COLOR MARK | YES |
COLOR(S) CLAIMED (If applicable) |
The color(s) pink and blue is/are claimed as a feature of the mark. |
*DESCRIPTION OF THE MARK (and Color Location, if applicable) |
The mark consists of a stylized circle design with "NEUROCRINE BIOSCIENCES" in block lettering. |
PIXEL COUNT ACCEPTABLE | YES |
PIXEL COUNT | 944 x 250 |
REGISTER | Principal |
APPLICANT INFORMATION | |
*OWNER OF MARK | Neurocrine Biosciences, Inc. |
*MAILING ADDRESS | 12780 El Camino Real |
*CITY | San Diego |
*STATE (Required for U.S. applicants) |
California |
*COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | United States |
*ZIP/POSTAL CODE (Required for U.S. and certain international addresses) |
92130 |
*EMAIL ADDRESS | XXXX |
LEGAL ENTITY INFORMATION | |
TYPE | corporation |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY OF INCORPORATION | Delaware |
GOODS AND/OR SERVICES AND BASIS INFORMATION | |
INTERNATIONAL CLASS | 005 |
*IDENTIFICATION | Pharmaceutical preparations for human use; Pharmaceutical preparations for the diagnosis, prevention and treatment of psychiatric, neurological, central nervous system, hormonal, genetic and movement diseases, disorders and conditions; pharmaceutical preparations for human use for diagnosis, prevention and treatment of diseases and disorders by gene therapy; pharmaceuticals for human use for the treatment of rare and orphan diseases, disorders and conditions; pharmaceutical preparations for the treatment of congenital adrenal hyperplasia |
FILING BASIS | SECTION 1(b) |
INTERNATIONAL CLASS | 042 |
*IDENTIFICATION | Research and development services in the fields of pharmaceuticals and biotechnology; pharmaceutical drug development services in the field of psychiatric, neurological, central nervous system, hormonal, genetic and movement diseases, disorders and conditions |
FILING BASIS | SECTION 1(b) |
INTERNATIONAL CLASS | 044 |
*IDENTIFICATION | Providing medical information; providing medical information in the field of psychiatric, neurological, central nervous system, hormonal, genetic and movement diseases, disorders and conditions; on-line information services, namely, providing medical information in the field of psychiatric, neurological, central nervous system, hormonal, genetic and movement diseases, disorders and conditions |
FILING BASIS | SECTION 1(b) |
ATTORNEY INFORMATION | |
NAME | Allison Strickland Ricketts |
ATTORNEY DOCKET NUMBER | NEUB 2110212 |
ATTORNEY BAR MEMBERSHIP NUMBER | XXX |
YEAR OF ADMISSION | XXXX |
U.S. STATE/ COMMONWEALTH/ TERRITORY | XX |
FIRM NAME | Fross Zelnick Lehrman & Zissu, P.C. |
STREET | 151 West 42nd St., 17th Floor |
CITY | New York |
STATE | New York |
COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | United States |
ZIP/POSTAL CODE | 10036 |
EMAIL ADDRESS | ricketts-docket@fzlz.com |
OTHER APPOINTED ATTORNEY | all other attorneys in firm |
CORRESPONDENCE INFORMATION | |
NAME | Allison Strickland Ricketts |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE | ricketts-docket@fzlz.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) | antonucci-docket@fzlz.com |
FEE INFORMATION | |
APPLICATION FILING OPTION | TEAS Standard |
NUMBER OF CLASSES | 3 |
APPLICATION FOR REGISTRATION PER CLASS | 350 |
*TOTAL FEES DUE | 1050 |
*TOTAL FEES PAID | 1050 |
SIGNATURE INFORMATION | |
SIGNATURE | /David L Bradfute/ |
SIGNATORY'S NAME | David L. Bradfute, PhD, JD |
SIGNATORY'S POSITION | Vice President & Head, Intellectual Property |
DATE SIGNED | 08/16/2021 |
SIGNATURE METHOD | Sent to third party for signature |
PTO- 1478 |
Approved for use through 08/31/2021. OMB 0651-0009 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |
Serial Number: 90884742 |
Filing Date: 08/16/2021 |
The applicant's current Correspondence Information: |
Allison Strickland Ricketts |
PRIMARY EMAIL FOR CORRESPONDENCE: ricketts-docket@fzlz.com SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): antonucci-docket@fzlz.com Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS). |
|
|